<DOC>
	<DOCNO>NCT01936571</DOCNO>
	<brief_summary>Lung cancer common cancer type worldwide , 1.1 million annual death . There two type disease , namely non-small cell lung cancer ( NSCLC ) small-cell lung cancer ( SCLC ) , first account 85 % total number case . The 5-year survival across stage remain disappointingly low , around 10 % country , due high incidence loco-regional distant failure [ 3 ] . However , last decade improve radiotherapy technique allow increase radiation dose , time effective chemo radiation scheme apply . These development lead improve outcome term survival . As TNM stag system highly inaccurate prediction survival outcome non-surgical patient , attempt make develop accurate risk stratification patient [ 1,2 ] . A model base clinical variable yield AUC 0.74 , encouraging , also leave room improvement [ 2 ] . An extended model , include clinical well biomarker variable , reach high AUC , limited number patient include study make impossible draw definitive conclusion [ 1 ] . New prognostic parameter retrieve several source , include anatomic , molecular functional imaging , genomics , proteomics clinical analysis patient . The unlimited amount information expect lead accurate prediction individual treatment outcome [ 4 ] . The analysis biomarkers , include protein , fast develop , promise challenge area research . Biomarkers measure evaluate normal biological process , pathogenic process , pharmacological response therapeutic intervention . Oncoproteins produce , response tumor cell , may secrete circulation patient . As tissue sample often possible lung cancer patient , blood sample collection venepuncture offer attractive alternative , safe easy implement . A number study describe prognostic predictive value blood biomarkers NSCLC [ 5-7 ] . In study investigate prognostic value blood biomarkers relate 1 ) hypoxia : Osteopontin ( OPN ) , carbonic anhydrase IX ( CA-9 ) , lactate dehydrogenase ( LDH ) ; 2 ) inflammation - interleukin 6 ( IL-6 ) , IL-8 , C-reactive protein ( CRP ) , α-2-macroglobulin ( α-2M ) ; 3 ) tumor load : Carcinoembryonic antigen ( CEA ) cytokeratin fragment ( CYFRA 21-1 ) . 1 . Dehing-Oberije C , Aerts H , Yu S , De Ruysscher D , Menheere P , Hilvo M , et al . Development validation prognostic model use blood biomarker information prediction survival non-small-cell lung cancer patient treat combined chemotherapy radiation radiotherapy alone ( NCT00181519 , NCT00573040 , NCT00572325 ) . Int J Radiat Oncol Biol Phys . 2011 Oct 1 ; 81 ( 2 ) :360-368 . 2 . Dehing-Oberije C , Yu S , De Ruysscher D , Meersschout S , Van Beek K , Lievens Y , et al . Development external validation prognostic model 2-year survival non-small-cell lung cancer patient treat chemoradiotherapy . Int J Radiat Oncol Biol Phys . 2009 Jun 1 ; 74 ( 2 ) :355-362 . 3 . Travis WD , Brambilla E , Müller-Hermelink HK , Harris CC . World Health Organization Classification Tumours : Pathology Genetics Tumours Lung , Pleura , Thymus Heart . Paul Kleihues MD , Leslie H. Sobin MD , editor . Lyon , France : IARC Press , International Agency Research Cancer ; 2004 . 4 . Lambin P , Rios-Velazquez E , Leijenaar R , Carvalho S , van Stiphout RG , Granton P , et al . Radiomics : extract information medical image use advanced feature analysis . Eur J Cancer . 2012 Mar ; 48 ( 4 ) :441-446 . 5 . Donati V , Boldrini L , Dell'Omodarme M , Prati MC , Faviana P , Camacci T , et al . Osteopontin expression prognostic significance non-small cell lung cancer . Clin Cancer Res . 2005 Sep 15 ; 11 ( 18 ) :6459-6465 . 6 . Muley T , Fetz TH , Dienemann H , Hoffmann H , Herth FJ , Meister M , et al . Tumor volume tumor marker index base CYFRA 21-1 CEA strong prognostic factor operate early stage NSCLC . Lung Cancer . 2008 Jun ; 60 ( 3 ) :408-415 . 7 . Pine SR , Mechanic LE , Enewold L , Chaturvedi AK , Katki HA , Zheng YL , et al . Increased level circulate interleukin 6 , interleukin 8 , C-reactive protein , risk lung cancer . J Natl Cancer Inst . 2011 Jul 20 ; 103 ( 14 ) :1112-1122 .</brief_summary>
	<brief_title>Usefulness Blood Biomarkers Overall Survival NSCLC</brief_title>
	<detailed_description>Lung cancer common cancer type worldwide , 1.1 million annual death . There two type disease , namely non-small cell lung cancer ( NSCLC ) small-cell lung cancer ( SCLC ) , first account 85 % total number case . The 5-year survival across stage remain disappointingly low , around 10 % country , due high incidence loco-regional distant failure [ 3 ] . However , last decade improve radiotherapy technique allow increase radiation dose , time effective chemo radiation scheme apply . These development lead improve outcome term survival . As TNM stag system highly inaccurate prediction survival outcome non-surgical patient , attempt make develop accurate risk stratification patient [ 1,2 ] . A model base clinical variable yield AUC 0.74 , encouraging , also leave room improvement [ 2 ] . An extended model , include clinical well biomarker variable , reach high AUC , limited number patient include study make impossible draw definitive conclusion [ 1 ] . New prognostic parameter retrieve several source , include anatomic , molecular functional imaging , genomics , proteomics clinical analysis patient . The unlimited amount information expect lead accurate prediction individual treatment outcome [ 4 ] . The analysis biomarkers , include protein , fast develop , promise challenge area research . Biomarkers measure evaluate normal biological process , pathogenic process , pharmacological response therapeutic intervention . Oncoproteins produce , response tumor cell , may secrete circulation patient . As tissue sample often possible lung cancer patient , blood sample collection venepuncture offer attractive alternative , safe easy implement . A number study describe prognostic predictive value blood biomarkers NSCLC [ 5-7 ] . In study investigate prognostic value blood biomarkers relate 1 ) hypoxia : Osteopontin ( OPN ) , carbonic anhydrase IX ( CA-9 ) , lactate dehydrogenase ( LDH ) ; 2 ) inflammation - interleukin 6 ( IL-6 ) , IL-8 , C-reactive protein ( CRP ) , α-2-macroglobulin ( α-2M ) ; 3 ) tumor load : Carcinoembryonic antigen ( CEA ) cytokeratin fragment ( CYFRA 21-1 ) . 1 . Dehing-Oberije C , Aerts H , Yu S , De Ruysscher D , Menheere P , Hilvo M , et al . Development validation prognostic model use blood biomarker information prediction survival non-small-cell lung cancer patient treat combined chemotherapy radiation radiotherapy alone ( NCT00181519 , NCT00573040 , NCT00572325 ) . Int J Radiat Oncol Biol Phys . 2011 Oct 1 ; 81 ( 2 ) :360-368 . 2 . Dehing-Oberije C , Yu S , De Ruysscher D , Meersschout S , Van Beek K , Lievens Y , et al . Development external validation prognostic model 2-year survival non-small-cell lung cancer patient treat chemoradiotherapy . Int J Radiat Oncol Biol Phys . 2009 Jun 1 ; 74 ( 2 ) :355-362 . 3 . Travis WD , Brambilla E , Müller-Hermelink HK , Harris CC . World Health Organization Classification Tumours : Pathology Genetics Tumours Lung , Pleura , Thymus Heart . Paul Kleihues MD , Leslie H. Sobin MD , editor . Lyon , France : IARC Press , International Agency Research Cancer ; 2004 . 4 . Lambin P , Rios-Velazquez E , Leijenaar R , Carvalho S , van Stiphout RG , Granton P , et al . Radiomics : extract information medical image use advanced feature analysis . Eur J Cancer . 2012 Mar ; 48 ( 4 ) :441-446 . 5 . Donati V , Boldrini L , Dell'Omodarme M , Prati MC , Faviana P , Camacci T , et al . Osteopontin expression prognostic significance non-small cell lung cancer . Clin Cancer Res . 2005 Sep 15 ; 11 ( 18 ) :6459-6465 . 6 . Muley T , Fetz TH , Dienemann H , Hoffmann H , Herth FJ , Meister M , et al . Tumor volume tumor marker index base CYFRA 21-1 CEA strong prognostic factor operate early stage NSCLC . Lung Cancer . 2008 Jun ; 60 ( 3 ) :408-415 . 7 . Pine SR , Mechanic LE , Enewold L , Chaturvedi AK , Katki HA , Zheng YL , et al . Increased level circulate interleukin 6 , interleukin 8 , C-reactive protein , risk lung cancer . J Natl Cancer Inst . 2011 Jul 20 ; 103 ( 14 ) :1112-1122 . The investigator hypothesize : - Higher level blood biomarkers associate bad survival - The biomarker information improve performance prediction model , previously develop validate [ 1 , 2 ] - Subgroups patient identify benefit term accurate prediction survival use biomarker information Measurement procedure : Blood sample , collect , process store Maastro biobank standardized way , use measure CRP , LDH , Osteopontin , CA-9 IL-6 , IL-8 , CEA , CYFRA 21-1 , α-2M . Clinical data retrieve electronic medical file .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>The cohort consist approximately 250 patient . As rule thumb 510 event per variable need avoid overfitting model . To model 6 clinical variable + 9 biomarker variable 75150 event need . Assuming twoyear survival 40 % , calculate ( constant ) hazard rate 0.46 per year . With inclusion rate 50 patient per year , followup time vary 0.5 4 year , time analysis ( November/December 2013 ) expect 138 event available analysis .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>